Noisy
← this week  ·  Subscribe →

The world is being quietly rearranged by people who write very long documents.

Federal Register · May 9, 2025
The title they went with Medical Devices; Immunology and Microbiology Devices; Classification of the DNA-Based Test To Measure Minimal Residual Disease in Hematological Malignancies Noisy translates that to

New DNA tests for blood cancers can now reach patients with fewer regulatory hurdles

What happened
US health regulators just made it easier for new DNA tests to detect tiny traces of blood cancer. This means manufacturers can bring these important diagnostic tools to market with less regulatory burden.
Why it matters
Getting new medical tests approved by US health regulators often means navigating a complex system. This rule creates a specific, less burdensome path for DNA tests that find tiny amounts of cancer cells after treatment. It means patients with blood cancers could get access to better monitoring tools sooner.
The signal
Watch how quickly new DNA tests for minimal residual disease in blood cancers appear on the market in the next 12-24 months.
If you insist
Read the original →